On
The phase III study, which started
'With more than 750 patients recruited to date, we are pleased to receive this favorable outcome. It is also reassuring that the futility analysis demonstrates statistical support for the continuation of the study', says CEO
About
IBT is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby preventing or treating rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world's first approved probiotic drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Contact:
CEO
Bryggargatan 10
111 21 Stockholm
Telefon: +46 8 410 145 55
E: info@ibtherapeutics.com
WEB: www.ibtherapeutics.com
(C) 2022 Electronic News Publishing, source